Company profile
Waiv, formerly Owkin Dx
Pioneering AI precision testing in oncology
- Industry
- Biotechnology Research
- Employees
- 52
- Headquarters
- Paris
- Founded
- 2026
- Office locations
- 1
Waiv, formerly Owkin Dx company summary
Waiv, formerly Owkin Dx is a company in the Biotechnology Research industry, headquartered in Paris, founded in 2026. On LinkedIn the company has around 52 employees. Its listed specialties include Artificial Intelligence, Histomics Technology, Oncology, Drug Discovery, Medical Research.
What technology does Waiv, formerly Owkin Dx use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Waiv, formerly Owkin Dx
Waiv has evolved to meet this moment: Hundreds of novel innovations are entering clinical development each year, while biomarker testing complexity and costs are surging. As healthcare undergoes a broader shift toward precision care, treatment decisions, monitoring strategies, and patient pathways increasingly rely on high-dimensional data and advanced diagnostics. Clinical diagnostics must keep pace with the scale and complexity of precision medicine, ensuring no patient is left behind. Waiv, a spin-out of Owkin (https://www.owkin.com/), capitalizes on its industry-leading tech & AI stack, and clinically validated, already-deployed AI tests, such as RlapsRisk BC (https://www.owkin.com/diagnostics/rlapsrisk-bc), to unlock morphological insights and future-proof the clinical diagnostic workflow.
Specialties
Where is Waiv, formerly Owkin Dx located?
Waiv, formerly Owkin Dx lists 1 location.
Compare companies similar to Waiv, formerly Owkin Dx
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Waiv, formerly Owkin Dx wearewaiv.com | Biotechnology Research | 52 | 2026 | Paris |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Waiv, formerly Owkin Dx
What does Waiv, formerly Owkin Dx do?
Waiv has evolved to meet this moment: Hundreds of novel innovations are entering clinical development each year, while biomarker testing complexity and costs are surging. As healthcare undergoes a broader shift toward precision care, treatment decisions, monitoring strategies, and patient pathways increasingly rely on high-dimensional data and advanced diagnostics. Clinical diagnostics must keep pace with the scale and complexity of precision medicine, ensuring no patient is left behind. Waiv, a spin-out of Owkin (https://www.owkin.com/), capitalizes on its industry-leading tech & AI stack, and clinically validated, already-deployed AI tests, such as RlapsRisk BC (https://www.owkin.com/diagnostics/rlapsrisk-bc), to unlock morphological insights and future-proof the clinical diagnostic workflow.
How many employees does Waiv, formerly Owkin Dx have?
Waiv, formerly Owkin Dx has around 52 employees on LinkedIn.
Where is Waiv, formerly Owkin Dx headquartered?
Waiv, formerly Owkin Dx is headquartered in Paris.
When was Waiv, formerly Owkin Dx founded?
Waiv, formerly Owkin Dx was founded in 2026.
Build a lead list from companies like Waiv, formerly Owkin Dx
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.